Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immune-Related Rheumatological and Neurological Adverse Events Study
NL-OMON58755Phase 2Recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- May 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2 trial of nivolumab and relatlimab, sponsored by Amsterdam University Medical Center. Started May 2023; status: recruiting.
02
Drugs
nivolumabrelatlimab
Beyond the preview
Go deeper on NL-OMON58755.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58755.